GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Common Stock

Argenica Therapeutics (ASX:AGN) Common Stock : A$16.92 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Common Stock?

Argenica Therapeutics's quarterly common stock increased from Dec. 2022 (A$13.07 Mil) to Jun. 2023 (A$16.62 Mil) and increased from Jun. 2023 (A$16.62 Mil) to Dec. 2023 (A$16.92 Mil).

Argenica Therapeutics's annual common stock increased from Jun. 2021 (A$8.05 Mil) to Jun. 2022 (A$13.07 Mil) and increased from Jun. 2022 (A$13.07 Mil) to Jun. 2023 (A$16.62 Mil).


Argenica Therapeutics Common Stock Historical Data

The historical data trend for Argenica Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Common Stock Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Common Stock
8.05 13.07 16.62

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial 8.04 13.07 13.07 16.62 16.92

Argenica Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Argenica Therapeutics (ASX:AGN) Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines